BIO 2013 Monday Roundup: Bayer, Orphan Drug Pricing, Avalon/GSK

23 Apr 2013

• By Wendy Diller, Alex Lash, and Chris Morrison

Our survey of news from the first day of BIO 2013 includes a look at Bayer’s business development plans, Avalon Ventures’ tie-up with GlaxoSmithKline, and news from panel discussions on orphan drugs, venture philanthropy and Russia.

BIO 2013 Monday Roundup: Bayer, Orphan Drug Pricing, Avalon/GSK

More from United States

More from North America